Navigation Links
PDL BioPharma Elects Barry Selick to Its Board of Directors
Date:8/3/2009

INCLINE VILLAGE, Nev., Aug. 3 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced the appointment of Harold E. ("Barry") Selick, Ph.D., to the Company's Board of Directors.

"Barry's experience as a seasoned biotechnology executive and his extensive knowledge of PDL's humanization technology will allow him to make valuable contributions to our strategy and operations as we seek to maximize the value of our antibody humanization patents and related assets and monetize these assets for our stockholders," said John McLaughlin, president and chief executive officer of PDL.

Dr. Selick has served as chief executive officer of Threshold Pharmaceuticals since June 2002. From January 1999 to April 2002, he was chief executive officer of biotechnology company Camitro Corporation. From 1992 to 1999, he worked at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as vice president of Research. Prior to joining Affymax, he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he was a co-inventor of the technology underlying the creation of fully humanized antibody therapeutics and applied this technology to PDL's first product, Zenapax (R), which was developed and commercialized by Roche for the prevention of kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

About PDL BioPharma, Inc.

PDL BioPharma pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The company receives royalties on sales of a number of humanized antibody products marketed today and also may receive royalty payments on additional humanized antibody products launched before patent expiry in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
2. PDL BioPharma Announces Second Quarter 2009 Financial Results
3. PDL BioPharma to Announce Second Quarter 2009 Financial Results and Hold Conference Call July 30, 2009
4. DOR BioPharma Appoints Christopher P. Schnittker, CPA, as Vice President of Administration and Controller
5. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
6. Helix Biopharma Corp. Begins Trading on the OTCQX International Market Listing as HXBPF
7. Sinobiopharma Receives Trademark Approval and Authentication From Chinese Government For Its Tai Drug Series
8. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
9. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
10. PDL BioPharma Announces Record Date for October 1 Dividend Payment
11. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan Carlisle Agency, ... Jefferson County, is announcing the launch of a charity drive to raise support ... homeless women and children in Birmingham has grown steadily since the 1980’s, and ...
(Date:12/8/2016)... Wichita, KS (PRWEB) , ... December 08, 2016 ... ... and financial consultation services to families and business owners in and around central ... to provide assistance to at-risk youth in the region. , Headquartered in Wichita, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... in their bodies, a researcher at the Icahn School of Medicine at Mount ... The study found that when young children are exposed to secondhand marijuana smoke, ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning ... to an emergency medical call when he lost control of his patrol car. The ... from his vehicle, he was transported to Atlanta Medical Center, where he later succumbed ...
(Date:12/7/2016)... MA (PRWEB) , ... December 07, 2016 , ... They ... They are sisters and wives, brothers and fathers, from New England and around the ... and its stigma, and are brought together in a beautiful and compelling new photographic ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- Global Cervical Dysplasia Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
(Date:12/7/2016)... 2016  Palatin Technologies, Inc. ("Palatin") (NYSE MKT: ... previously disclosed underwritten public offering of units with ... sole book-running manager, Roth Capital Partners acted as ... co-manager for the offering. "This financing ... proceeds, allowing us to continue advancing bremelanotide for ...
(Date:12/7/2016)... NEW YORK , Dec. 7, 2016 /PRNewswire/ ... This report on pulmonary drugs studies the current ... globally. The stakeholders of this report include companies ... of various pulmonary/respiratory drugs and/or drug-device combinations as ... market. This report comprises an elaborate executive summary ...
Breaking Medicine Technology: